Molecular Partners Ag Stock Alpha and Beta Analysis
| MOLN Stock | USD 4.21 0.01 0.24% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Molecular Partners AG. It also helps investors analyze the systematic and unsystematic risks associated with investing in Molecular Partners over a specified time horizon. Remember, high Molecular Partners' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Molecular Partners' market risk premium analysis include:
Beta (0.56) | Alpha 0.3 | Risk 4.13 | Sharpe Ratio 0.0512 | Expected Return 0.21 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Molecular Partners market risk premium is the additional return an investor will receive from holding Molecular Partners long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Molecular Partners. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Molecular Partners' performance over market.| α | 0.30 | β | -0.56 |
Molecular Partners expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Molecular Partners' Buy-and-hold return. Our buy-and-hold chart shows how Molecular Partners performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Molecular Partners Market Price Analysis
Market price analysis indicators help investors to evaluate how Molecular Partners stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Molecular Partners shares will generate the highest return on investment. By understating and applying Molecular Partners stock market price indicators, traders can identify Molecular Partners position entry and exit signals to maximize returns.
Molecular Partners Return and Market Media
The median price of Molecular Partners for the period between Wed, Oct 8, 2025 and Tue, Jan 6, 2026 is 4.12 with a coefficient of variation of 7.21. The daily time series for the period is distributed with a sample standard deviation of 0.29, arithmetic mean of 4.08, and mean deviation of 0.25. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 | 11/03/2025 |
2 | How buybacks impact Molecular Partners AG Depositary Receipt stock value - Earnings Growth Report Entry Point Confirmation Alerts - newser.com | 11/07/2025 |
3 | Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action | 11/12/2025 |
4 | Will Molecular Partners AG stock boost dividends further - July 2025 Sentiment Weekly Breakout Stock Alerts - newser.com | 11/17/2025 |
5 | Can Molecular Partners AG Depositary Receipt stock deliver strong Q4 earnings - Quarterly Earnings Summary High Yield Equity Trading Tips - newser.com | 11/20/2025 |
6 | Will Molecular Partners AG stock beat revenue estimates - 2025 Major Catalysts Fast Gain Stock Tips - Newser | 12/01/2025 |
7 | Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting - TipRanks | 12/08/2025 |
8 | Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference | 12/18/2025 |
9 | Hemadri Cements Limited Tests 50 Day MA After Sharp Decline - Dividend Reinvestment Plans Low Risk Trading Alerts - Bollywood Helpline | 12/22/2025 |
About Molecular Partners Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Molecular or other stocks. Alpha measures the amount that position in Molecular Partners has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 90.5 | 81.45 | 73.3 | 69.64 | PTB Ratio | 0.64 | 0.98 | 1.12 | 1.07 |
Molecular Partners Upcoming Company Events
As portrayed in its financial statements, the presentation of Molecular Partners' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Molecular Partners' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Molecular Partners' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Molecular Partners. Please utilize our Beneish M Score to check the likelihood of Molecular Partners' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Molecular Partners
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Molecular Partners Backtesting, Molecular Partners Valuation, Molecular Partners Correlation, Molecular Partners Hype Analysis, Molecular Partners Volatility, Molecular Partners History and analyze Molecular Partners Performance. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Molecular Partners technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.